Document Detail


Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
MedLine Citation:
PMID:  9732927     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Lanreotide is a somatostatin analogue whose activity persists for 10-14 days. In this study, we treated a group of patients with gastrointestinal endocrine tumors with lanreotide to assess its therapeutic efficacy and tolerability. METHODS: Eighteen patients, 12 male and six female, mean age 58 yr (range, 25-80 yr) were studied. Ten had carcinoid tumors, five had nonfunctioning endocrine tumors, two had glucagonomas, and the remaining one had a gastrinoma. All patients had somatostatin receptors, demonstrated by octreoscan scintigraphy. Lanreotide was administered intramuscularly at a dose of 30 mg every 10 days, for a mean of 12 months (range, 5-18 months). Fifteen of the 18 patients had been previously treated with octreotide. RESULTS: In patients with carcinoid tumors, lanreotide markedly reduced daily bowel movements and flushing episodes. A reduction was also observed in urinary serotonin and urinary 5-hydroxyindoleacetic acid, although it was not statistically significant. A marked reduction in symptoms, and in plasma glucagon and serum gastrin levels, was also observed in patients with glucagonoma and gastrinoma. In the five patients with nonfunctioning endocrine tumors, as in all the other 13 patients, no significant effects were noted in the size of the tumor. The administration of lanreotide did not cause side effects, apart from transient abdominal pain and pain at the injection site in two patients. Only in the patient with gastrinoma was lanreotide suspended, because of the appearance of attacks of marked hypoglycemia. In the 15 patients previously treated with octreotide, no differences in the effects were noted with lanreotide. CONCLUSIONS: Lanreotide has a satisfactory therapeutic efficacy and tolerability in the treatment of gastrointestinal endocrine tumors; its effects are similar to those of octreotide. However, unlike octreotide, it can be administered once every 10-14 days, instead of 2 or 3 times daily and for this reason, it is preferable in clinical practice.
Authors:
P Tomassetti; M Migliori; L Gullo
Related Documents :
2412557 - Neuropeptide k: a major tachykinin in plasma and tumor tissues from carcinoid patients.
15075907 - Treatment of carcinoid of the lung.
1651057 - Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carc...
25427507 - Synthesis and characterization of near ir fluorescent albumin nanoparticles for optical...
19088397 - Successful combined treatment of primary cardiac malignant lymphoma with urgent cardiac...
9020917 - Inhibition of peritoneal dissemination of colon carcinoma in syngeneic mice immunized w...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  93     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1998-09-15     Completed Date:  1998-09-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1468-71     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine and Gastroenterology, University of Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects,  therapeutic use*
Carcinoid Tumor / drug therapy
Delayed-Action Preparations
Endocrine Gland Neoplasms / drug therapy*
Female
Gastrinoma / drug therapy
Gastrointestinal Neoplasms / drug therapy*
Glucagonoma / drug therapy
Humans
Male
Middle Aged
Peptides, Cyclic / adverse effects,  therapeutic use*
Somatostatin / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Delayed-Action Preparations; 0/Peptides, Cyclic; 118992-92-0/lanreotide; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical status of ulcerative colitis in patients who smoke.
Next Document:  Proliferative patterns of rectal mucosa as predictors of advanced colonic neoplasms in routinely pro...